Spago Nanomedical AB (publ) (STO:SPAGO)
Sweden · Delayed Price · Currency is SEK 0.1255
-0.0040 (-3.09%)
Jan 21, 2026, 4:17 PM CET
Spago Nanomedical AB Company Description
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden.
Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage.
The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.
The company was incorporated in 1999 and is based in Lund, Sweden.
Spago Nanomedical AB (publ)
| Country | Sweden |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Mats Hansen |
Contact Details
Address: ScheelevAegen 22 Lund, 223 63 Sweden | |
| Phone | 46 4 68 11 88 |
| Website | spagonanomedical.se |
Stock Details
| Ticker Symbol | SPAGO |
| Exchange | Nasdaq Stockholm |
| Share Class | Class B Shares |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0004899474 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mats Hansen M.Sc., Ph.D. | Chief Executive Officer |
| Hanna Olsson M.Sc. | Chief Financial Officer |
| Paul Hargreaves | Chief Development Officer |